Le Lézard
Classified in: Health
Subject: PLW

Romeg Therapeutics Announces Issuance of U.S. Patent for Pilocarpine Oral Solution

WOBURN, Mass., Feb. 1, 2023 /PRNewswire/ -- ROMEG Therapeutics, LLC ("Romeg"), an innovative drug development company focused on alternative formulations to better meet clinical and patient needs, today announced that the United States Patent and Trademark Office has issued U.S. Patent No. 11,564,909 (the '909 patent) directed to the methods and composition of ROMEG's proprietary formulation of pilocarpine. The '909 patent reflects a significant addition to Romeg's current intellectual property portfolio and covers the composition claims of pilocarpine oral solution and its therapeutic indications.

"We are pleased with the USPTO's issuance of the '909 patent today," said Naomi Vishnupad, Ph.D., Chief Scientific Officer and Partner of Romeg. "There is a high unmet need for more patient-friendly formulations of pilocarpine and the allowance of the first patent in our pilocarpine portfolio will facilitate our continued progress towards developing a therapeutic option that will benefit patients in need."

Currently, patients requiring pilocarpine as therapy for dry mouth (xerostomia), including patients who have undergone head and neck radiation therapy and Sjogren's Syndrome, have only the option of a solid tablet dosed three to four times daily. Xerostomia patients often have significant difficulty swallowing tablets, necessitating a therapeutic option that is easier to administer, such as a liquid dosage form. Romeg is committed to addressing the need of these patients with a palatable, easy to administer pilocarpine oral solution therapy.

About Romeg 

ROMEG Therapeutics, LLC, is a privately held specialty pharmaceutical company based in Woburn, Mass. The company's mission is to develop new FDA-approved therapies by formulating novel dosage forms, improving the design and function of existing approved drugs, and expanding clinical indications for use of those drugs, thereby bringing greater value to earlier scientific discovery. The company is focused on developing a broad intellectual property portfolio to offer novel therapies to provide patients and physicians better treatment options. For more information, visit www.romegrx.com.

Media Contact: [email protected]

SOURCE Romeg Therapeutics, LLC

These press releases may also interest you

at 07:25
United Network for Organ Sharing (UNOS) has rolled out a new organ allocation system designed to be more equitable and effective for patients in need of lung transplants....

at 07:14
Significant Progress in Clinical Trials for Core Products Reinforces Leading Position in RNA Therapeutics with Strong Product Pipeline Matrix Business Highlights Clinical developmentSTP705-  The part-one Phase IIb interim data on STP705 for the...

at 07:10
Harrow , a leading U.S. eyecare pharmaceutical company, today announced that it has entered into a $100 million secured credit financing agreement with funds managed by Oaktree Capital Management, L.P. ("Oaktree"). The interest-only secured credit...

at 07:10
ANANDA Scientific Inc., a research focused bio-pharmaceutical company today announced that the first subject has been enrolled in the clinical trial with an FDA-approved IND evaluating Nantheiatm A1002N5S, an investigational drug using cannabidiol...

at 07:10
Silence Therapeutics plc, Nasdaq: SLN ("Silence" or "the Company"), an experienced and innovative biotechnology company committed to transforming people's lives by silencing diseases through precision engineered medicines, today announced the...

at 07:09
Hangzhou Tigermed Consulting Co., Ltd. ("Tigermed" or the "company") (Stock code: 300347.SZ / 3347.HK), a leading provider of clinical research solutions across full lifecycle of global biopharmaceutical and medical device products, announced its...

News published on 1 february 2023 at 09:04 and distributed by: